Table 2.
Outcomes in Clenbuterol and Placebo Groups
| Test | Clenbuterol |
Placebo |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Baseline | Week 52 | Change | pa | n | Baseline | Week 52 | Change | p | |
| 6MWT (m) | 6 | 373 | 389 | 4% | 0.08 | 4 | 567 | 587 | 4% | 0.33 |
| 6MWT (%) | 6 | 58 | 61 | 5% | 0.03 | 4 | 81 | 85 | 5% | 0.3 |
| GSGC (pt) | 6 | 16 | 14 | −13% | 0.004* | 4 | 8 | 7 | −13% | 0.21 |
| QMFT (pt) | 5 | 40 | 47 | 18% | 0.007* | 4 | 54 | 56 | 4% | 0.20 |
| FEV1 (%) | 7 | 58 | 65 | 12% | 0.06 | 4 | 86 | 88 | 2% | 0.28 |
| FVC (%) | 7 | 60 | 64 | 7% | 0.11 | 4 | 83 | 90 | 8% | 0.25 |
| MEP (%) | 5 | 40 | 54 | 35% | 0.06 | 4 | 63 | 49 | −22% | 0.12 |
| MIP (%) | 5 | 51 | 69 | 35% | 0.004 | 4 | 97 | 104 | 7% | 0.28 |
| GAA (μmol/min/g tissue) | 6 | 0.14 | 0.18 | 29% | <0.05 | 4 | 0.20 | 0.15 | −25% | 0.47 |
| Glycogen | 7 | 0.75 | 0.37 | −51% | 0.007* | 4 | 0.73 | 0.88 | 21% | 0.34 |
| LAMP2 (relative to GAPDH) | 5 | 0.69 | 0.46 | −33% | 0.01 | 3 | 0.88 | 1.2 | 36% | 0.04 |
a
p by t test shown. If p < 0.05 by two-way ANOVA, indicated by an asterisk (*).